19 withdrawn. 19 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 19 | Withdrawn 19 |
| Phase 2 | 2 | Withdrawn 2 |
Follow Depressive Disorder: new trials by email Literature Review of Depressive Disorder trials Research Report on Depressive Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Perinatal Synergistic Multi-component Intervention to alLeviate dEpressive Symptoms. A Case Series interpersonal psychotherapy (IPT), Ketamine - Postpartum Depression | Phase 2 / Phase 3 | Withdrawn | Washington University School of Medicine | 2025-10-15 | 2025-10-29 | |
| A Study to Evaluate the Efficacy and Safety of REL-1017 As Adjunctive Treatment of Major Depressive Disorder (MDD) REL1017 (esmethadone HCI) (active drug), Placebo - Major Depressive Disorder (MDD) | Phase 3 | Withdrawn | MGGM LLC | 2024-12-27 | 2025-02-07 | |
| Anti-suicidal Effects of Buprenorphine In Depressed Individuals Belbuca Buccal Product, Placebo - Suicidal Ideation, Major Depressive Disorder | Phase 3 | Withdrawn | New York State Psychiatric Institute | 2022-10-10 | 2023-11-14 | |
| Neurobiology of Treatment Responses in MDD Duloxetine, Placebo - Major Depressive Disorder | Phase 3 | Withdrawn | University of Utah | 2021-11-01 | 2023-04-24 | |
| ECT vs. Esketamine Esketamine nasal spray, Electroconvulsive therapy - Treatment Resistant Depression, Major Depressive Disorder | Phase 3 | Withdrawn | Medical University Innsbruck | 2021-07-28 | 2022-08-05 | |
| A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg - Depressive Disorder, Treatment-Resistant | Phase 3 | Withdrawn | Janssen-Cilag International NV | 2019-12-01 | 2025-04-27 | |
| Endogenous Opioid Modulation by Ketamine Ketamine Hydrochloride, Normal saline - Major Depressive Disorder | Phase 3 | Withdrawn | University of Utah | 2019-08-01 | 2020-01-28 | |
| Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD) Rapastinel, Vortioxetine, Placebo - Depressive Disorder, Major | Phase 3 | Withdrawn | Naurex, Inc, an affiliate of Allergan plc | 2019-07-01 | 2019-07-19 | |
| Neural and Antidepressant Effects of Propofol (Phase 2) Diprivan - Treatment Resistant Depression | Phase 2 / Phase 3 | Withdrawn | University of Utah | 2019-04-16 | 2019-12-18 | |
| Treatment for Cognitive Impairment in Depression Modafinil, Placebo - Major Depressive Disorder | Phase 3 | Withdrawn | Stanford University | 2018-12-01 | 2020-03-20 | |
| Deep Brain Stimulation to Relieve Depression Medtronic Activa SC DBS, Lead Model 3387 - Treatment Resistant Depression | Phase 3 | Withdrawn | Jordan F. Karp | 2018-06-01 | 2018-08-06 | |
| Vortioxetine for the Treatment of Major Depression and Co-morbidities After Traumatic Brain Injury (TBI) Vortioxetine, Placebo - TBI, Major Depression | Phase 3 | Withdrawn | Johns Hopkins University | 2016-10-01 | 2016-09-02 | |
| Brexpiprazole (OPC 34712) Trial in the Treatment of Adults With Major Depressive Disorder and Irritability Brexpiprazole - Major Depressive Disorder and Irritability | Phase 3 | Withdrawn | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2014-09-01 | 2016-07-07 | |
| Major Depressive Disorder With Mixed Features Lurasidone 20 mg, Lurasidone 60 mg, Placebo - Major Depressive Disorder | Phase 3 | Withdrawn | Sumitomo Pharma America, Inc. | 2012-01-01 | 2012-12-13 | |
| Optimal Duration of Olanzapine Add-on Therapy in Major Depression Olanzapine - Relapse Rate of a Major Depressive Episode, Safety of Olanzapine in Subjects With Major Depression | Phase 3 | Withdrawn | Charite University, Berlin, Germany | 2007-10-01 | 2023-02-09 | |
| Olanzapine Augmentation Therapy in Treatment-resistant Depression: a Double-blind Placebo-controlled Trial Olanzapine, Placebo - Therapy-resistant Depression | Phase 3 | Withdrawn | University Hospital Freiburg | 2005-06-01 | 2022-08-10 | |
| Aripiprazole Augmentation Therapy in Treatment-resistant Depression Aripiprazole - Therapy-resistant Depression | Phase 3 | Withdrawn | University Hospital Freiburg | 2005-06-01 | 2022-08-10 | |
| Discontinuation Study Of Citalopram (Antidepressant) in Depressed Adolescents Citalopram - Major Depression | Phase 3 | Withdrawn | Sunnybrook Health Sciences Centre | 60 | 2002-09-01 | 2006-09-19 |
| The Effectiveness of Idazoxan in Treating TRD Idazoxan - Major Depressive Disorder | Phase 3 | Withdrawn | Sheba Medical Center | 2008-01-29 |
Depressive Disorder, Major (13) · Depressive Disorder, Treatment-Resistant (6) · Depression (2) · Affective Disorders, Psychotic (1) · Depression, Postpartum (1) · Mental Disorders (1) · Suicidal Ideation (1)
Mood Disorders (19) · Mental Disorders (18) · Behavior (3) · Behavioral Symptoms (3) · Female Urogenital Diseases and Pregnancy Complications (1) · Pregnancy Complications (1) · Puerperal Disorders (1) · Schizophrenia Spectrum and Other Psychotic Disorders (1) · Self-Injurious Behavior (1) · Suicide (1) · Urogenital Diseases (1)
Duloxetine Hydrochloride (2) · Ketamine (2) · Olanzapine (2) · Vortioxetine (2) · Aripiprazole (1) · Bupropion (1) · Citalopram (1) · Electroconvulsive Therapy (1) · Escitalopram (1) · Esketamine (1) · GLYX-13 peptide (1) · Idazoxan (1) · Interpersonal Psychotherapy (1) · Lurasidone Hydrochloride (1) · Mirtazapine (1)
University of Utah (3) · University Hospital Freiburg (2) · Charite University, Berlin, Germany (1) · Janssen-Cilag International NV (1) · Johns Hopkins University (1) · Jordan F. Karp (1) · MGGM LLC (1) · Medical University Innsbruck (1) · Naurex, Inc, an affiliate of Allergan plc (1) · New York State Psychiatric Institute (1) · Otsuka Pharmaceutical Development & Commercialization, Inc. (1) · Sheba Medical Center (1) · Stanford University (1) · Sumitomo Pharma America, Inc. (1) · Sunnybrook Health Sciences Centre (1)
United States (7) · Germany (3) · Austria (1) · Canada (1) · Israel (1) · Italy (1) · Switzerland (1)
Claus Normann, MD (2) · Anthony J Levitt, MD (1) · Arnim Quante, MD (1) · David Monks, MBCHB (1) · Ion Anghelescu, MD (1) · Jeffrey M Miller, MD (1) · Joseph Zohar, MD (1) · Junichi Hashimoto, PhD (1) · Marc Debelle (1) · Mina M Rizk, MD (1) · Vani Rao, MD (1)
2018 (2)